Highlights
- •Patients with multiple sclerosis should be informed about pregnancy issues.
- •Fingolimod should be discontinued at least two months before pregnancy.
- •Previous human studies have reported possible risk of congenital abnormalities following Fingolimod exposure during the first weeks of gestation.
- •Here we report a 33 year old patient with MS who had unexpected pregnancy with exposure to generic Fingolimod in the first weeks.
- •The infant was born with dextrocardia without any other structural or conductive heart abnormalities.
Abstract
Fingolimod, taken orally once per day, is approved for the treatment of relapsing-remitting
multiple sclerosis (MS). It should be stopped at least two months before conception
as it is not considered safe during pregnancy or when breast feeding. In vitro and
animal studies have found a possibly increased risk of congenital abnormalities following
exposure to Fingolimod. Here, we report a 34-year-old female, with a 10-year history
of MS who had unexpected pregnancy with exposure to generic Fingolimod during the
first 7 weeks. The infant was born with dextrocardia, but without any further structural
cardiac or other abnormalities
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Multiple Sclerosis and Related DisordersAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
Agency, E.M., 2013. Gilenya: EPAR: Product Information (updated July 2012). 〈http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf.57〉.
- Pregnancy and the use of disease-modifying therapies in patients with multiple sclerosis: benefits versus risks.Mult. Scler. Int. 2016; : 1034912
- Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology.Pharmacol. Ther. 2007; 115: 84-105
- Management of women with multiple sclerosis through pregnancy and after childbirth.Ther. Adv. Neurol. Disord. 2016; 9: 198-210
Geissbühler, Y., Vile, J., Koren, G. et al., 2016. 〈http://onlinelibrary.ectrims-congress.eu/ectrims/2016/32nd/146555/yvonne.geissbhler.cumulative.data.on.pregnancy.outcomes.after.exposure.to.html〉.
- Multiple sclerosis and pregnancy: therapeutic considerations.J. Neurol. 2013; 260: 1202-1214
- Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis.Neurology. 2014; 82: 674-680
- Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence.Ther. Adv. Neurol. Disord. 2016; 9: 130-147
- Isolated dextrocardia and congenital heart blocking.Radiol. Case Rep. 2013; 8: 521
- Risk factors for heart disease associated with abnormal sidedness.Teratology. 2002; 66: 242-248
Article info
Publication history
Published online: February 15, 2018
Accepted:
February 10,
2018
Received in revised form:
January 28,
2018
Received:
March 9,
2017
Identification
Copyright
© 2018 Elsevier B.V. All rights reserved.
